Sam H James

发表

Effects of frequent hemodialysis on measures of CKD mineral and bone disorder.

T. Greene, A. Kliger, G. Chertow, 2012, Journal of the American Society of Nephrology : JASN.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Debra F. Weinstein, Michael G. Miller, M. A. Ferreira, 2019, Lancet.

Characteristics of AA amyloidosis patients in San Francisco

K. Jen, J. Olson, Sam H James, 2016, Nephrology.

Leukocyte chemotactic factor 2: A novel renal amyloid protein.

K. Scott, J. Liepnieks, M. Benson, 2008, Kidney international.

Lupus-like membranous nephropathy: Is it lupus or not?

K. Jen, M. Schwartz, F. Amani, 2015, Clinical and Experimental Nephrology.

Impact of Sleep Quality on Cardiovascular Outcomes in Hemodialysis Patients: Results from the Frequent Hemodialysis Network Study

Christopher T. Chan, M. Unruh, A. Kliger, 2011, American Journal of Nephrology.

In-center hemodialysis six times per week versus three times per week.

G. Beck, M. Rocco, S. Rajagopalan, 2010, The New England journal of medicine.

Risk of vascular access complications with frequent hemodialysis.

M. Rocco, A. Kliger, P. Eggers, 2013, Journal of the American Society of Nephrology : JASN.

Specialist and primary care physicians’ views on barriers to adequate preparation of patients for renal replacement therapy: a qualitative study

Jessica M. Ameling, Raquel C. Greer, N. Powe, 2015, BMC Nephrology.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Debra F. Weinstein, Michael G. Miller, M. A. Ferreira, 2019, Lancet.